Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and ...

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

“They can’t hurt,” said Jared Holz, healthcare equity strategist and sector specialist at Mizuho Securities. “Anything that Kim does, I’ll do it,” Holz quipped, drawing laughs ...

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share. With the closely watched XBI biotech index down 13% for the year, every M&A ...

Mizuho Americas healthcare equity strategist Jared Holz joins Market Domination with Josh Lipton and Julie Hyman to explain why he's telling clients to stay away from the stock for now.

On February 21, Jared Holz, Mizuho Securities America’s healthcare sector strategist, appeared on CNBC to discuss Trump’s tariffs and their effects on the American pharma sector. Although he ...

Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in ...

"The stock shakes off almost every fundamental issue/set-back and still manages to outperform most peers," wrote Mizuho healthcare equity strategist Jared Holz in a note to clients on Nov. 10 ...